erratum report replac origin version publish
march origin report depict model imag
incorrect correct version model imag
delet correct model imag ad
upgrad buy pt littl late
parti sign sale stabil need
upgrad buy establish pt four
reason upgrad first weve track entir sale organ
 linkedin sinc start year see earli sign
stabil growth telegraph management spoke
anecdot progress recent confer track result
comfort given sale forc challeng second
expect management repeat mistak past specif take
conserv approach guidanc provid revenu rang
last quarterli call also maintain rang
even midst view beatabl sale
forc addit rep combin new rep hire
see matur rep previous assum even
overal sale forc tenur declin new hire layer
matur rep model assum product gain rest
sale forc fall near high end guidanc give us
level comfort number third regardless outcom
recon interim look expect receiv bla avanc
time may push back patient need trial
think avanc ultim receiv bla even avanc doesnt receiv
bla isnt limit sell avanc hct/p fourth
attend aao axgn potenti acquir talk
leverag ratio improv believ could list
hire rapid pace end march rep
analysi rep axgn
definit product year higher model
assum estim sale forc
past year grow rep hire
could wrong sale leadership pivot sale forc
strategi territori split result rep leav could see growth
sputter rep begin reach upper bound market
capac growth may limit
valuat rate buy pt base
estim month revenu risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
four reason upgrad
sign sale forc stabil
tough end combin decreas top-lin
guidanc view poor explan around sale forc
dynam left lot investor uncertain happen within
compani forward end march sale forc pictur look
better new leadership place sinc januari rep
number gone steadili encourag
analysi one person within sale organ either left
let go compani sinc start track januari note
analysi limit linkedin profil appear larg
repres base discuss management
use definit matur rep month
account product believ investor begin gain comfort
around top-lin growth expect assum averag matur rep
sale per rep maturing/new rep averag
blend rate new rep less matur rep
independ agent previous assum lower
proport sale forc matur review everi
person profil linkedin start see tenur sale forc
better weve previous assum add new hire
matur rep categori reach number closer higher end
guidanc add slight product increas could get back
good old day beat expect
factor guidanc
low-end guidanc assum product gain modest price
increas matur legaci rep combin rep hire grow
territori contribut littl expect put new hire
point
defin matur rep compani
month prior commenc join earlier
matur rep reach month hire
new rep
compani twelv month hire later
current averag tenur within sale forc month
slightli decemb averag tenur month
make sens given grow proport new hire
hire rep
asid thought would help investor know axogen
hire rep varieti medic technolog compani doesnt
appear one compani larg bolu disband sale forc
acquisit view posit lifecel allergan
lavin smith nephew snn rate buy pt
contribut rep newer group rep late
bit choppi term sale forc dynam doesnt appear
misstep hamper abil hire
believ management learn chang compani
provid guidanc street result provid revenu
rang oppos static growth percentag estim provid
rang scenario also provid investor better clariti around management
think either end rang addit believ beat
guidanc may remain place overshoot expect ye
larg got compani troubl last year guidanc
walk novemb analyst day
look consensu believ expect
growth inher lower base management commentari around new sale
forc leadership chang worri around continu disrupt sale
forc linger work issu
doesnt seem impact result extent management may initi
thought mean though revenu guidanc slam
dunk growth expect meaning higher would
short-sight think well could equal well
therefor expect management keep guidanc intact come
compani see improv product
would expect lift guidanc think
take step-wis approach year make us
comfort upgrad last year wait consensu
number came felt share approach
multipl outcom recon think avanc
expect report interim statist analysi regard
recon studi avanc recal recon studi multicent
prospect random subject evalu blind compar studi
nerv cuff avanc nerv graft evalu recoveri outcom
repair nerv discontinu recon primari object studi
evalu differ function recoveri outcom studi
object interim statist analysi determin need
add patient beyond first trial order properli
power studi statist signific patient equal
statist power higher likelihood achiev statist
signific outcom said patient may also impli
outcom may closer initi estim treatment arm
control arm patient ad depend mani
could view neg
initi would expect share regardless mani
patient ad weve contempl outcom weve come
believ said done receiv bla fda
avanc regardless studi size total data
alreadi shown combin rmat design avanc
compani view larg de-risk trial give us level
confid bla like reason trial goe awri
still abl sell avanc hct/p pathway extrem
see like
ultim uncertain whether investor view statist look
non-ev neg would surmis share
investor add posit opportunist
complementari acquisit multipl larg cap
come american academi orthopaed surgeon annual
meet clear us larg orthoped player
buy zimmer biomet neutral smith nephew snn
rate intent acquisit small mid-siz tuck-in
complement larg sale forc sale channel fit well
within profil compani larger strateg acquir would
explor acquir would axogen product accret gross
margin compani larger compani strip axogen
much cost make asset ep accret quit rapidli
addit larger compani necessarili need keep entir
sale forc given alreadi larg distribut
consid leverag ratio zimmer biomet smith nephew
net debt/adj ebitda zimmer biomet still
higher leverag ratio smith nephew easili abl
acquir cash immedi purchas compani
without issu addit debt zimmer state plan
acquisit pay debt believ
three compani plu other could look pick-up premium
current valuat even deal amort would add meaning
ep growth
rate buy pt base estim
month revenu estim believ improv sale forc
ntm pt entxentneutr pt medicaltcmdneutr medicalwmginot factset data btig ptpricemarket cap bp/eev/salescagrev/ebitda
headcount combin higher proport matur rep give us
confid around revenu expect multipl in-lin
high growth med-tech peer grow lower rate
given challeng seen late feel multipl in-lin
group appropri time risk rate pt includ sale forc
dynam product distributor sale forc dynam competit
larger player fda regulatori risk clinic trial success ip
incom etot y/i sale oper incom incom tax expens net incom share net net oper expens btig estim compani report
revenu growthav y/i y/i y/i y/i q/q q/q q/q q/q sale rep etot distribut chanelmatur rep rep new rep quarter rep rep month rep rep rep accountsnew btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
